[{"id":"e994ddd8-c8c2-48db-9917-ca57ceffe9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04995185","created_at":"2021-08-06T12:53:11.830Z","updated_at":"2024-07-02T16:35:03.536Z","phase":"","brief_title":"18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study","source_id_and_acronym":"NCT04995185","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" HIF1A • CA9","pipe":" | ","alterations":" HIF1A expression • VEGFA expression • CA9 expression","tags":["HIF1A • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • VEGFA expression • CA9 expression"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/20/2017","start_date":" 06/20/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2024-05-15"},{"id":"30b7368a-f8fa-42a9-b19a-c1d96001eccd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00499083","created_at":"2021-01-18T01:47:11.312Z","updated_at":"2024-07-02T16:35:35.156Z","phase":"Phase 2","brief_title":"Paclitaxel, Cyclophosphamide \u0026 Doxorubicin, Autologous Dendritic Cells \u0026 Surgery in Stage II/III Breast Cancer (Women)","source_id_and_acronym":"NCT00499083","lead_sponsor":"University of Nebraska","biomarkers":" HER-2 • CEACAM5 • PTGS2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression","tags":["HER-2 • CEACAM5 • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • tamoxifen • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Soltamox (tamoxifen citrate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 01/28/2010","study_completion_date":" 01/28/2010","last_update_posted":"2023-09-29"},{"id":"3f0eee4c-cc3f-47e5-8775-fa046060ec8c","acronym":"EPMLARF","url":"https://clinicaltrials.gov/study/NCT04081805","created_at":"2023-09-14T17:11:53.239Z","updated_at":"2024-07-02T16:35:36.920Z","phase":"","brief_title":"LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)","source_id_and_acronym":"NCT04081805 - EPMLARF","lead_sponsor":"Federal University of São Paulo","biomarkers":" MMP2 • MMP9 • MMP1 • MMP3","pipe":" | ","alterations":" VEGFA expression","tags":["MMP2 • MMP9 • MMP1 • MMP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 195","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-09-14"},{"id":"6b88056b-740c-4793-8c44-c7eb87101b2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01555268","created_at":"2021-01-18T06:35:03.601Z","updated_at":"2024-07-02T16:36:04.006Z","phase":"Phase 1","brief_title":"Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01555268","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" VEGFA • CD34","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 10/31/2011","start_date":" 10/31/2011","primary_txt":" Primary completion: 09/24/2013","primary_completion_date":" 09/24/2013","study_txt":" Completion: 08/03/2016","study_completion_date":" 08/03/2016","last_update_posted":"2022-09-13"},{"id":"d495ee7e-d85d-48a4-b68e-e3738b8a1f1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03759496","created_at":"2021-01-18T18:28:40.380Z","updated_at":"2024-07-02T16:36:14.810Z","phase":"Phase 2","brief_title":"Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer","source_id_and_acronym":"NCT03759496","lead_sponsor":"Hellenic GenitoUrinary Cancer Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • VEGFA expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 11/15/2018","start_date":" 11/15/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-03-23"},{"id":"e2f4220b-368a-4d6f-ba44-2b13c683e1d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01125046","created_at":"2021-01-23T00:52:22.369Z","updated_at":"2024-07-02T16:36:35.684Z","phase":"Phase 2","brief_title":"Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas","source_id_and_acronym":"NCT01125046","lead_sponsor":"Northwestern University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • VEGFA expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/17/2010","start_date":" 06/17/2010","primary_txt":" Primary completion: 03/10/2014","primary_completion_date":" 03/10/2014","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2021-01-22"},{"id":"6cf01444-c1ba-4242-8878-f81aebdd9b12","acronym":"ESCEND","url":"https://clinicaltrials.gov/study/NCT03877601","created_at":"2021-01-18T19:06:50.238Z","updated_at":"2024-07-02T16:36:39.173Z","phase":"Phase 2","brief_title":"Detection of Early Esophageal Cancer by NIR-FME.","source_id_and_acronym":"NCT03877601 - ESCEND","lead_sponsor":"University Medical Center Groningen","biomarkers":" VEGFA","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2020-11-04"},{"id":"4e732152-20ea-453a-8b1d-4f7519c28cbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01596790","created_at":"2021-01-18T06:49:32.961Z","updated_at":"2024-07-02T16:36:42.350Z","phase":"","brief_title":"COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01596790","lead_sponsor":"University Hospital, Montpellier","biomarkers":" VEGFA","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 09/01/2019","study_completion_date":" 09/01/2019","last_update_posted":"2020-08-05"},{"id":"1bb4d7b2-4893-4f4d-8e8b-cacb5b89aeb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02072720","created_at":"2021-01-18T09:33:00.104Z","updated_at":"2024-07-02T16:36:54.973Z","phase":"Phase 1","brief_title":"Angiogenic Factor Expression During Fractionated Irradiation","source_id_and_acronym":"NCT02072720","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" KDR • CD31 • PECAM1","pipe":" | ","alterations":" KDR expression • VEGFA expression","tags":["KDR • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-10-02"},{"id":"8ecb7624-1e34-46a2-8e81-e407b465fc51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00052611","created_at":"2021-01-18T00:05:52.353Z","updated_at":"2024-07-02T16:37:12.672Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia","source_id_and_acronym":"NCT00052611","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1","pipe":" | ","alterations":" BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression","tags":["BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2002","start_date":" 06/01/2002","primary_txt":" Primary completion: 03/01/2005","primary_completion_date":" 03/01/2005","study_txt":" Completion: 03/01/2005","study_completion_date":" 03/01/2005","last_update_posted":"2018-03-29"},{"id":"c679c891-db2e-48af-a57b-9b8c26706382","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381797","created_at":"2021-01-18T01:19:39.832Z","updated_at":"2024-07-02T16:37:16.033Z","phase":"Phase 2","brief_title":"Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma","source_id_and_acronym":"NCT00381797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KDR • EPAS1 • CA9","pipe":" | ","alterations":" VEGFA overexpression • VEGFA expression • CA9 expression","tags":["KDR • EPAS1 • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA overexpression • VEGFA expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-11-28"},{"id":"c64e4a08-e403-4230-ab36-3d42a457255d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00159484","created_at":"2021-01-18T00:32:30.508Z","updated_at":"2025-02-25T15:47:20.936Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00159484","lead_sponsor":"University of Southern California","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 expression • VEGFA expression","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral • patupilone (EPO 906)"],"overall_status":"Unknown status","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-06-27"},{"id":"4a4f2a29-2521-49a7-9367-367885eef7fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01156168","created_at":"2021-01-18T04:36:13.151Z","updated_at":"2024-07-02T16:37:22.061Z","phase":"","brief_title":"Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab","source_id_and_acronym":"NCT01156168","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" VEGFA","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 363","initiation":"Initiation: 04/05/2011","start_date":" 04/05/2011","primary_txt":" Primary completion: 09/08/2011","primary_completion_date":" 09/08/2011","study_txt":" Completion: 09/08/2011","study_completion_date":" 09/08/2011","last_update_posted":"2017-05-17"}]